2752-50-3

Basic information

• Product Name: N-phenylacetylvaline
• Synonyms: N-phenylacetylvaline
• CAS NO: 2752-50-3
• Molecular Weight: 235.283
• Mol File: 2752-50-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-phenylacetylvaline(CAS DataBase Reference)
• NIST Chemistry Reference: N-phenylacetylvaline(2752-50-3)
• EPA Substance Registry System: N-phenylacetylvaline(2752-50-3)

Safety Data

• Hazardous Substances Data: 2752-50-3(Hazardous Substances Data)

Upstream product

• 516-06-3 D,L-valine 
• 103-80-0 phenylacetyl chloride 
• 33054-04-5 phenylacetyl azide 

Downstream Products

• 20776-98-1 N-phenylacetyl-D-valine 
• 725-67-7 (2S)-3-Methyl-2-[(phenylmethyl)carbonyl]aminobutyric acid 

Relevant articles and documents

Penicillin G acylase-mediated kinetic resolution of racemic 1-(N-acylamino)alkylphosphonic and 1-(N-acylamino)alkylphosphinic acids and their esters

Extensive studies on the penicillin G acylase-mediated kinetic resolution of N-acylated 1-aminoalkylphosphonic and 1-aminoalkylphosphinic acids as well as their esters were carried out to recognise the relationships between the substrate structure, reacti

N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Composition containing a penem or carbapenem antibiotic and the use of the same

Administration of an N-acylated amino acid in association with a penem or carbapenem antibiotic relieves or eliminates the renal problems associated with administration of the antibiotic alone. The amino acid derivative and antibiotic may be formulated together as a composition or administered separately, either simultaneously or sequentially.